DRF-1042 is a DNA topoisomerase I inhibitor potentially for the treatment of solid tumors. References: Chatterjee A, Digumarti R, Katneni K, Upreti VV, Mamidi RN, Mullangi R, Surath A, Srinivas ML, Uppalapati S, Jiwatani S, Srinivas NR. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60. PubMed PMID: 15778426.

纯度：≥98%

CAS：200619-13-2